

RESULTS OF ANNUAL GENERAL MEETING

Perth, Australia; 20 November 2019: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises that its 2019 Annual General Meeting was held today, 20 November 2019. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against	Abstain
1	Non-Binding Resolution to adopt Remuneration Report	14,011,571	528,674	864,470
2	Re-election of Doctor Stewart Washer as a Director	29,874,399	285,818	9,220
3	Ratification of issue of Options to consultants under ASX Listing Rule 7.1	29,249,798	468,398	451,241
4	Ratification of issue of Shares under ASX Listing Rule 7.1	28,556,000	678,128	56,309
5	Ratification of issue of Shares under ASX Listing Rule 7.1A	29,439,500	683,628	46,309
6	Approval of 10% Placement Facility.	29,474,553	668,310	26,574
7	Authority to Grant Plan Options to a Director- Professor Lars Lidgren or his Nominated Party	14,587,511	722,640	94,564
8	Authority to Grant Plan Options to a Related Party- Ms Nicole Telford or her Nominated Party	14,513,426	776,725	114,564

Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Non-Binding Resolution to adopt Remuneration Report	13,428,917	528,674	425,358	439,112
2	Re-election of Doctor Stewart Washer as a Director	28,504,696	285,818	472,632	9,220
3	Ratification of issue of Options to consultants under ASX Listing Rule 7.1	27,862,139	468,398	490,588	451,241



4	Ratification of issue of Shares under ASX Listing Rule 7.1	27,168,341	678,128	490,588	56,309
5	Ratification of issue of Shares under ASX Listing Rule 7.1A	28,051,841	683,628	490,588	46,309
6	Approval of 10% Placement Facility.	28,067,065	688,310	510,417	26,574
7	Authority to Grant Plan Options to a Director- Professor Lars Lidgren or his Nominated Party	13,488,499	722,640	516,358	94,564
8	Authority to Grant Plan Options to a Related Party- Ms Nicole Telford or her Nominated Party	13,414,414	776,725	516,358	114,564

Simon Robertson
Company Secretary

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
Hales² Communications

P: +61 423 139 163

E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US and AUS. The Company's other major product is TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. Orthocell is moving forward with clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

